Yaupon locks up phase II Clearazide trial
Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma.
Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma.
The randomized study, slated for completion in 2010, has enrolled 260 patients from 13 cancer centers. Clearazide is a topical form of nitrogen mustard, an alkylating agent that works by inhibiting DNA replication.
Articles in this issue
New Doxil-based regimens don’t fly with FDA advisors
Four steps to improve the profitability of your oncology practice
Mathematical model predicts resistance to Herceptin
ASTRO issues guide on accelerated breast radiotherapy
Study renews breast ca link to migraines
Sutent shows promise for brain metastases in NSCLC patients
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
